Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2004

View Archived Issues

New peptide sulfonamides and their use as integrin receptor modulators

New antitumor agents and their use in ALL therapy

Novel glucagon antagonists covered by Merck patent

Phamacopeia scientists claim new IL-8 receptor modulators

Novartis presents new cathepsin S inhibitors with utility in neuropathic pain

Daiichi scientists prepare and test new factor Xa inhibitors

New antibacterial agent isolated from Fundibacter sp. by Japanese researchers

Merck KGaA grants vilazodone rights to Genaissance

European approval for Angiox for use in PCI

New perspectives in the use of sumatriptan to treat migraine

RGH-896 demonstrates in vivo analgesia

Lower infection rate found in some volunteers after receiving bivalent HIV vaccines

Patient recruitment starts in a phase I clinical trial with DAC:GRF

IND submission to begin clinical testing of Tarvacin

Clinical trials confirm the efficacy of ropinirole in PD and RLS

Advisory Committee recommends approval of Menactra

Long-term clinical evaluation of three treatments for early PD

Pivotal study begins for FavId for follicular B-cell NHL

NF-kappaB Decoy set to enter phase I/II trial in 2005

Canadian sites approved to join pivotal Veronate study

Promising early results for escitalopram in treatment of kleptomania

RegeneRx files to begin phase II study of TB4 for chronic pressure ulcers

Enrollment completed in phase III study of Canvaxin

Sopherion licenses North American rights to Myocet

Paladin Labs realigns product pipeline

Alimta approved in Europe for malignant pleural mesothelioma and NSCLC

Enrollment under way in Modrenal prostate cancer study

Sertraline demonstrates potential in treating bulimia

DNA vaccine for anthrax effective in rabbit model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.